Research Papers and Book Chapters
April 2021
Size segregation of irregular granular materials captured by time-resolved 3D imaging
SEDA author(s): P. Gajjar
Date: April 2021
Published: Scientific Reports
April 2021
Crystallographic tomography and molecular modelling of structured organic polycrystalline powders
SEDA author(s): P. Gajjar
Date: April 2021
Published: CrystEngComm
Feb 2021
Analysis of Fixed and Live Single Cells Using Optical Photothermal Infrared with Concomitant Raman Spectroscopy
SEDA author(s): J. Denbigh
Date: Feb 2021
Published: Analytical Chemistry
Jan 2021
Exploring a model-based analysis of patient derived xenograft studies in oncology drug development
SEDA author(s): J. Dickinson, M. de Matas, P.A. Dickinson, H. Mistry
Date: Jan 2021
Published: PeerJ
Jan 2021
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
SEDA author(s): C. Patterson
Date: Jan 2021
Published: Communications Biology
Dec 2020
Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge
SEDA author(s): C. Patterson
Date: Dec 2020
Published: Advanced Drug Delivery Reviews
Nov 2020
IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies
SEDA author(s): C. Patterson, S. Budhdeo
Date: Nov 2020
Published: European Journal of Pharmaceutics and Biopharmaceutics
Jul 2020
Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products
SEDA author(s): P.A. Dickinson
Date: Jul 2020
Published: The AAPS Journal
May 2020
Novel application of synchrotron x-ray computed tomography for ex-vivo imaging of subcutaneously injected polymeric microsphere suspension formulations
SEDA author(s): C. Patterson
Date: May 2020
Published: Pharmaceutical Research
Dec 2018
Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin
SEDA author(s): P.A. Dickinson
Date: Dec 2018
Published: British Journal of Clinical Pharmacology
Jun 2018
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib
SEDA author(s): P.A. Dickinson
Date: Jun 2018
Published: British Journal of Clinical Pharmacology
May 2018
Nonclinical safety and pharmacokinetics of Miglyol 812: A medium chain triglyceride in exenatide once weekly suspension
SEDA author(s): C. Patterson
Date: May 2018
Published: Journal of Applied Toxicology
Apr 2018
The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small cell lung cancer and in healthy volunteers
SEDA author(s): P.A. Dickinson
Date: Apr 2018
Published: Journal of Clinical Pharmacology
Sep 2017
Emerging trends in therapeutic algorithm of chronic wound healers: Recent advances in drug delivery systems, concepts-to-clinical application, and future prospects
SEDA author(s): M. de Matas
Date: Sep 2017
Published: Critical Reviews™ in Therapeutic Drug Carrier Systems
Mar 2017
The impact of formulation attributes and process parameters on black seed oil loaded liposomes and their performance in animal models of analgesia
SEDA author(s): M. de Matas
Date: Mar 2017
Published: Saudi Pharmaceutical Journal
Nov 2016
Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid
SEDA author(s): P.A. Dickinson
Date: Nov 2016
Published: Journal of Pharmaceutical Sciences
Sep 2016
Clinical pharmacology profile of an oral selective androgen receptor down-regulator, AZD3514: Implications on the design of ongoing castrate-resistant prostate cancer clinical studies
SEDA author(s): P.A. Dickinson
Date: Sep 2016
Published: Cancer Research Frontiers
Sep 2016
Asymmetric Distribution in Twin Screw Granulation
SEDA author(s): M. de Matas
Date: Sep 2016
Published: European Journal of Pharmaceutics and Biopharmaceutics
Aug 2016
Metabolic disposition of osimertinib in rat, dog, and man: insights into a drug designed to bind covalently to a cysteine residue of EGFR
SEDA author(s): P.A. Dickinson
Date: Aug 2016
Published: Drug Metabolism and Disposition
Jul 2016
Strategic framework for education and training in quality by design (QbD) and process analytical technology (PAT)
SEDA author(s): M. de Matas
Date: Jul 2016
Published: European Journal of Pharmaceutical Sciences
May 2016
Systems pharmacology modeling of prostate-specific antigen in prostate cancer patients treated with an androgen receptor antagonist and down-regulator
SEDA author(s): P.A. Dickinson
Date: May 2016
Published: CPT Pharmacometrics and Systems Pharmacology
Apr 2016
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies
SEDA author(s): P.A. Dickinson
Date: Apr 2016
Published: Cancer Chemotherapy and Pharmacology
Jan 2016
Clinically Relevant Dissolution for Low-Solubility Immediate-Release Products
SEDA author(s): P.A. Dickinson, P. Stott
Date: Jan 2016
Published: Poorly Soluble Drugs: Dissolution and Drug Release.
Invited Talks and Podium Presentations
Nov 2020
It’s all in the delivery
SEDA author(s): P. Stott
Date: Nov 2020
Published: Bio Integrates 2020, Digital Event
Nov 2020
Biopharmaceutics in Complex Parenteral Formulation Design
SEDA author(s): C. Patterson
Date: Nov 2020
Published: 2020 Bionow Oncology Conference, Digital Event
Jun 2020
In silico modelling: Subcutaneous Bioavailability of mAbs
SEDA author(s): C. Patterson
Date: Jun 2020
Published: In Roundtable: "Predicting Bioavailability of Monoclonal Antibodies after Subcutaneous Administration: Open Innovation Challenge. CRS Virtual Annual Meeting
Sep 2017
BioRAM: connecting the drug product with the patient – from design to optimized product
SEDA author(s): P.A. Dickinson
Date: Sep 2017
Published: The 8th APS International PharmSci Conference, University of Hertfordshire, Hatfield, UK
Jul 2017
Score sheet, Box 1: Early basic knowledge, starting point. From Blueprint to action: Getting to critical questions and knowledge.
SEDA author(s): P.A. Dickinson
Date: Jul 2017
Published: Applying the Biopharmaceutics Risk Assessment Roadmap (BioRAM): Patient-Focused Drug Development: Developing critical knowledge with BioRAM and the BioRAM Scoring Grid.The USP Meetings Center in Rockville, MD, USA
Oct 2016
Introduction to the Biopharmaceutics Risk Assessment Roadmap (BioRAM), Drug Delivery Scenarios and Scoring Grid
SEDA author(s): P.A. Dickinson
Date: Oct 2016
Published: EuPAT8, University College Cork, Cork, Ireland
Oct 2015
Clinically relevant specifications in practice: What have we learned since the QbD Pilot Program?
SEDA author(s): P.A. Dickinson
Date: Oct 2015
Published: In Roundtable: Clinically Relevant Specifications: Where Are We Now? AAPS Annual Meeting, Orange County Convention Center, Orlando, Fl, USA
Oct 2015
Pharmaceutical Quality: The dissolution test and clinically relevant specifications – impact on product development
SEDA author(s): P.A. Dickinson
Date: Oct 2015
Published: International Multidisciplinary Symposium on Drug Research and Development, Anadolu University, Eskişehir, Turkey
Oct 2015
Accelerating the development of drug products using advanced pharmaceutical design tools and manufacturing
SEDA author(s): M. de Matas
Date: Oct 2015
Published: International Multidisciplinary Symposium on Drug Research and Development, Anadolu University, Eskişehir, Turkey
Sep 2015
Design space considerations for dissolution methods
SEDA author(s): P.A. Dickinson
Date: Sep 2015
Published: Joint Pharmaceutical Analysis Group Symposium on the Impact of emerging regulatory guidelines on development and commercial activities at PharmSci 2015, East Midlands Conference Centre, Nottingham, UK
Sep 2015
Transforming promising molecules into valued medicines – the emerging Alderley Park Translational Science Ecosytem (APTrans)
SEDA author(s): M. de Matas
Date: Sep 2015
Published: PharmSci 2015, East Midlands Conference Centre, Nottingham, UK
Posters and Abstracts
Nov 2018
Analysis of patient derived xenograft studies in Oncology drug development: impact on design and interpretation of future studies
SEDA author(s): J. Dickinson, M. de Matas, P.A. Dickinson
Date: Nov 2018
Published: PKUK, Midland Hotel, Manchester, UK